Overview
Novoic uses artificial intelligence to analyze spoken language to detect early signs of Alzheimer’s disease. It offers a software-based 10-minute speech test that runs on any smart device and is used by medical institutions, with 50+ centers currently adopting the technology. The company aims to extend access to underserved communities where detection is scarce. Revenue comes from selling the software to healthcare providers. Its AI models are validated through Novoic’s own clinical trials and trained on diverse datasets to improve accuracy and fairness.
Work here?Claim your company
Simplify's Take
What believers are saying
- Novoic reports deployment in over 50 medical centers, showing real workflow adoption.
- AMYPRED Stage 1 stayed recruiting in August 2026, keeping clinical validation active.
- NHS and ADNI partnerships expand data access and strengthen reimbursement discussions.
What critics are saying
- Novoic last raised capital in July 2020; funding drought threatens commercial scale-up.
- Only seed financing and six employees limit FDA, CE, and US hospital expansion.
- Speech-biomarker rivals like Cognetivity and Altoida target the same pre-dementia screening market.
What makes Novoic unique
- Novoic's Storyteller automates speech biomarker screening for Alzheimer's across 50+ institutions.
- Its AMYPRED studies validate speech scores against biomarker-confirmed prodromal and preclinical Alzheimer's.
- ADNI4 and NHS participation give Novoic clinical credibility competitors struggle to match.
Help us improve and share your feedback! Did you find this helpful?